Percheron Therapeutics Limited has released a press release.
Quarterly Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Institutional Placement and proposed Share Purchase Plan SPP
- MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
- First Patient Dosed in ATL1102 Phase IIb DMD Trial
- Chief Executive Officer and Managing Director Appointment
- PIIb DMD trial approved in Bulgaria- UK, Australia advancing
Later from Percheron Therapeutics
- Intention to launch Share Purchase Plan
- Positive new DMD Combination Therapy Data in mdx mice
- Share Purchase Plan (SPP) Offer Booklet
- Antisense Share Purchase Plan (SPP) Raises $3.26 Million
- Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics